These data implicate intrinsic CFTR dysfunction in causing the blunted type I IFN signaling response seen in LPS-activated CF MDMs and show that clinically relevant CFTR modulators have the potential to rescue this phenotype in patient cells. The gene discussed is CFTR; the disease is cystic fibrosis.